$1.50−0.09 (−5.66%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Elicio Therapeutics (ELTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue history is too short to read a growth trend (through FY21), net margin −192.8%. Worth your attention in FY25: Share count (+442.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲23.8%
−39.6
FY21→FY25CAGR —
Free cash flow ($M)▲0.5%
−37.0
FY21→FY25CAGR —
Diluted EPS▲39.3%
−2.58
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+442.1%
2.8mn → 15.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$16.0K
−81.6% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Gross Operating Net
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.5824, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 28,312.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 433.0 | — | — |
Gross profit | — | — | — | — | — | 27,879.0 | — | — |
Research & development | 23,537.0 | 24,903.0 | 33,656.0 | 23,849.0 | 18,103.0 | 48,698.0 | ▼26.0% | −15.4% |
Selling, general & admin | 14,788.0 | 12,811.0 | 11,330.0 | 11,896.0 | 5,630.0 | 18,488.0 | ▲13.1% | −8.8% |
Total operating expenses | 38,325.0 | 37,714.0 | 44,986.0 | 35,745.0 | 23,733.0 | 67,186.0 | ▼16.2% | −13.4% |
Operating incomefeeds ROC rank | −38,325.0 | −37,714.0 | −44,986.0 | −35,745.0 | −23,733.0 | −39,307.0 | ▲16.2% | — |
Other income, net | 2,643.0 | −1,857.0 | −6,912.0 | 550.0 | −4,475.0 | −15,266.0 | — | — |
Pretax income | −35,682.0 | −39,571.0 | −51,898.0 | −35,195.0 | −28,208.0 | −54,573.0 | ▲23.8% | — |
Income tax | — | 0.0 | 0.0 | 0.0 | — | — | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −35,737.0 | −39,571.0 | −51,898.0 | −35,195.0 | −28,208.0 | −54,573.0 | ▲23.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | −2.58 | −4.25 | −6.96 | −12.90 | −19.30 | ▲39.3% | — |
Diluted shares (mn) | — | 15.31 | 12.20 | 5.06 | 3.00 | 2.82 | ▲25.5% | +52.6% |
| Margins | ||||||||
Gross margin | — | — | — | — | — | 98.5% | — | — |
Operating margin | — | — | — | — | — | −138.8% | — | — |
Net margin19th pct in Healthcare | — | — | — | — | — | −192.8% | — | — |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

